{"id":673,"date":"2008-10-17T00:00:00","date_gmt":"2008-10-17T00:00:00","guid":{"rendered":"https:\/\/1millionbestdownloads.com\/condition-psoriasis-safety-issues-prompt-fda-changes-to-psoriasis-drug-label\/"},"modified":"2008-10-17T00:00:00","modified_gmt":"2008-10-17T00:00:00","slug":"condition-psoriasis-safety-issues-prompt-fda-changes-to-psoriasis-drug-label","status":"publish","type":"post","link":"https:\/\/1millionbestdownloads.com\/condition-psoriasis-safety-issues-prompt-fda-changes-to-psoriasis-drug-label\/","title":{"rendered":"Safety Issues Prompt FDA Changes to Psoriasis Drug Label"},"content":{"rendered":"
By Theresa Tamkins Known as a boxed warning, the new label notes that Raptiva (efalizumab) can increase the risk of bacterial sepsis, an infection of the bloodstream; viral meningitis, which affects the brain; invasive fungal infections, which can damage the lungs or other areas of the body; and a condition known as progressive multifocal leukoencephalopathy (PML), a viral infection of the brain.<\/p>\n Several people taking Raptiva have been hospitalized and some have died due to these infections, according to the FDA.<\/p>\n The symptoms of PML include confusion, dizziness, vision problems, or difficulty talking or walking, the federal agency said. Other signs that require immediate medical attention include dizziness or weakness; abnormal bruising or bleeding gums; numbness or weakness in the arms, legs, or face; or worsening of psoriasis or arthritis.<\/p>\n In addition, animal studies have suggested that the drug may cause permanent suppression of the immune system in children. The drug is not approved for use in children under 18. The animal research was conducted in mice equivalent to ages 1 to 14 in humans.<\/p>\n
FRIDAY, Oct. 17 (Health.com) — The U.S. Food and Drug Administration (FDA) announced Thursday that it has updated the label for the psoriasis drug Raptiva to reflect the fact that the drug may increase the risk<\/a> of life-threatening opportunistic infections.<\/p>\n